NETs originate from neuroendocrine cells commonly found in the gut, lung or pancreas. A new tablet formulation of paltusotine is planned for use in both trials. This decline reached steady state in approximately seven days. Further, glucagon secretion was not suppressed in these experiments. Rescue of glyburide-induced hypoglycemia by CRN04777 in rats. If surgery is not an option, medical therapy may be used to block cortisol production. We own issued patents and patent applications relating to our product candidates. For these reasons, we may face competition with respect to our product candidates. The FDA will not approve the NDA without an approved REMS, if required. 2, San Diego, California 92121, and our telephone number is (858) 450-6464. The development of biopharmaceutical product candidates is capital-intensive. In addition, our product candidates, if approved, may not achieve commercial success. In either case, our development costs would increase. Obtaining and maintaining reimbursement status is time-consuming, costly and uncertain. In particular, there is intense competition in the field of endocrine disorders. Further, new studies may change the estimated incidence or prevalence of these diseases. The CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act, or CPRA, recently passed in California. Accordingly, the market price of shares of our common stock may decline. Litigation may be necessary to defend against these claims. Item 1B. Unresolved Staff Comments None.